Skip to main content
. 2017 Jun 14;13(8):1404–1419. doi: 10.1080/15548627.2017.1328347

Figure 3.

Figure 3.

Inhibition of the MTOR pathway by DRD5 activation. (A) Expression of AKT, p-AKT, MTOR, p-MTOR, EIF4EBP1, and p-EIF4EBP1 in GH3 cells after DRD5 agonist SKF83959 treatment at 25 μM by western blotting. (B) Histograms showing decreased p-EIF4EBP1, p-MTOR and p-AKT upon SKF83959 treatment. (C) DRD2 agonist quinpirole failed to reduce the expression of p-MTOR and p-EIF4EBP1 in GH3 cells by western blotting. (D) Drd5 KD abolished SKF83959-induced suppression of p-MTOR and p-EIF4EBP1 in GH3 cells by western blotting. (E) Overexpression of DRD5 in GH3 cells further enhanced SKF83959-induced p-MTOR and p-EIF4EBP1 reduction. **, p < 0.01; ***, p < 0.001.